Patents by Inventor Fumio Fukai

Fumio Fukai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activity enhancer for anticancer agent
    Patent number: 9327013
    Abstract: An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 3, 2016
    Assignees: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, SAGA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
    Inventors: Fumio Fukai, Hiroaki Kodama, Takuya Matsunaga
  • Remedy for chronic inflammation and antibody to be used therein
    Patent number: 9074184
    Abstract: The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: July 7, 2015
    Assignee: TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION
    Inventor: Fumio Fukai
  • Activity Enhancer for Anticancer Agent
    Publication number: 20140005120
    Abstract: An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.
    Type: Application
    Filed: March 9, 2012
    Publication date: January 2, 2014
    Applicant: TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Fumio Fukai, Hiroaki Kodama, Takuya Matsunaga
  • Remedy for Chronic Inflammation and Antibody to be Used Therein
    Publication number: 20110294985
    Abstract: The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).
    Type: Application
    Filed: February 4, 2010
    Publication date: December 1, 2011
    Applicant: Tokyo Universtiy of Science Educational Foundation Administrative Organization
    Inventor: Fumio Fukai
  • Physiologically active peptides
    Patent number: 6451971
    Abstract: Physiologically active peptides possessing cell adhesion inhibitory activity are provided. A physiologically active peptide of this invention is characterized by possessing cell adhesion inhibitory activity and comprising 30 amino acid residues or less, as well as by having an amino acid sequence of the formula: Gly Leu Lys Pro Gly Val Asp X1 Thr Ile Thr X2 X3 Ala X4 wherein X1 represents Tyr or Ala; X2 represents Val or Ala; X3 represents Tyr or Ala; and X4 represents Val or Ala.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: September 17, 2002
    Assignee: Hisamitsu Pharmaceutical Co., Ltd.
    Inventors: Katsuhiko Akiyama, Takeshi Goto, Fumio Fukai, Masaaki Ueki
  • Peptides derived from the heparin binding domain of fibronectin
    Patent number: 6274704
    Abstract: The biologically active peptide of the invention has a number of amino acids of 30 or less, comprises an amino acid sequence described as SEQ ID NO:13 (Tyr Thr Ile Tyr Val Ile Ala Leu) in the sequence listing and has cell adhesion inhibition activity. The peptide of the invention has short length and, therefore, synthesis and handling of the peptide are easy.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 14, 2001
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Fumio Fukai, Takashi Katayama